For the last year, Eli Lilly has been rapidly expanding a new website that connects patients with telehealth providers specialized in certain conditions it also sells drugs for, such as diabetes, obesity, and migraines. It’s now adding on another, one that pushes the envelope of telemedicine: Alzheimer’s.
Patients with conditions like obesity or migraines have the option of directly ordering medications on this platform, called LillyDirect, and getting them delivered to their home. Alzheimer’s patients won’t be able to order treatments, such as Lilly’s newly launched drug Kisunla, since they’re given as infusions in medical facilities.
Instead, they will be connected to Synapticure, a telehealth company that has neurologists who can diagnose patients virtually, arrange for them to get brain scans, and direct them to infusion centers if they do choose to get treatment. Patients will also have access to a tool to find local, in-person Alzheimer’s doctors.
Continue to STAT+ to read the full story…
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.